Cullgen, Inc., a US developer of a new drug discovery platform based on advanced ubiquitin-mediated protein degradation technology, raised a seed financing of up to $15M.
The round was led by GNI Group Ltd. (GNIG) (TOKYO: 2160).
Co-founded by Dr. Yue Xiong, William R. Kenan Professor of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, and Dr. Jian Jin, Professor of Pharmacological Sciences, Icahn School of Medicine, Mount Sinai, New York, Cullgen is a drug discovery company leveraging ubiquitin-mediated, small molecule-induced protein degradation technology.
The company’s research programs focus on novel treatment for cancer, inflammatory, and autoimmune diseases. .
Cullgen is incorporated in Delaware, USA and will concurrently initiate research operations in the United States, Japan and China.